title: [Therapeutic effect and its mechanism of "huo xue bu qi fang" on fetal rats with intrauterine growth retardation].
abstract: OBJECTIVE
  To probe into therapeutic effect and its mechanism of "Huo Xue Bu Qi Fang" (HXBQF) on fetal rats with intrauterine growth retardation (IUGR).
  
  
  METHODS
  The model of pregnant rat with IUGR was established by passive smoking method. Forty pregnant rats with IUGR were randomly divided into intervention group (with high-, middle- and low-dose Chinese traditional medicine) and non-intervention group. In addition, 10 normal pregnant rats were taken into control group. Intervention group was adminstered with 16.2, 5.4 and 1.62 g/kg HXBQF respectively. Non-intervention group and control group were administered with 10 ml/kg saline. Fetal rats were taken out, and blood and urine samples were collected from pregnant rats on day 21 of the pregnancy. The weight, nose-hip-length and poundera index of these fetal rats were measured. Serum NO, plasma ET-1 and urine 8-epi-PGF2 alpha level from pregnant rats were determined by nitro-reductase method, radioimmunoassay (RIA) and enzyme immunoassay (EIA) respectively.
  
  
  RESULTS
  Compared with fetal rats from non-intervention group, fetal weight, distance between nose-hip, poundera index serum NO level and NO/ET-1 were increased, plasma ET-1 level and urine 8-epi-PGF2 alpha level were decreased in those from intervention group (P < 0.01).
  
  
  CONCLUSIONS
  There is an enhancement of lipid peroxidation and NO/ET-1 ratio imbalance in pregnant rats with IUGR. HXBQF has good therapeutic effect on IUGR since it can inhibit lipid oxidation and regulate NO/ET-1 balance.
authors.affiliation: Pharmaceutic College, Jinan University, Guangzhou 510632.
authors.forename: Aihua
authors.initials: A
authors.lastname: Xiong
authors.forename: Xin
authors.initials: X
authors.lastname: Xiao
authors.forename: Chun
authors.initials: C
authors.lastname: Shuai
authors.forename: Xiuxiang
authors.initials: X
authors.lastname: Liu
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D001835:Body Weight; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000652:urine; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology*; D019332:Endothelin-1 / Q000097:blood; D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D009569:Nitric Oxide / Q000097:blood; D011247:Pregnancy; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000975:Antioxidants; D004365:Drugs, Chinese Herbal; D019332:Endothelin-1; C075750:8-epi-prostaglandin F2alpha; D009569:Nitric Oxide; D015237:Dinoprost